About Radius Ventures
Radius Ventures is a venture capital firm founded in 1997. It is primarily based out of New York City, United States. As of Jul 2018, Radius Ventures has invested in 33 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series I round of EndoGastric Solutions Overall, Radius Ventures portfolio has seen 2 IPOs and 22 acquisitions including key companies like Tactile Medical, Aethon and Amicus Therapeutics. A lot of funds co-invest with Radius Ventures, with names like Canaan sharing a substantial percentage of its portfolio. Radius Ventures has team of 6 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 5 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Radius Ventures' List of Top Investments
Radius Ventures has a portfolio of 33 companies. Their most notable investments are in Heartscape Technologies and Healthsense.Their portfolio spans across United States, Israel, Japan and 1 more locations. They have invested in Life Sciences, HealthTech, Enterprise Applications and 5 other sectors, across stages such as Series B, Series A and 5 more. Here is the list of top investments by Radius Ventures:Provider of lymphedema and venous ulcer treatment therapy and pumps. It has products for treating lymphedema (pumps) and chronic venous leg ulcers due to venous leg insufficiency in the home. Flexitouch System that's designed to mimic manual lymphatic drainage therapy. It also markets the ACTitouch System to treat chronic venous insufficiency.
Key facts about Tactile Medical
- Founded Year: 1995
- Location: Minneapolis (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $23.2M
- Employee Count: 1,131 as on Sep 30, 2026
- Investors: Sofia Fund, Galen Partners and 1 Other
- Latest Funding Round: Series B, Oct 16, 2012, $*****
- Highlight: Public
2. Aethon
Aethon offers automated hospital delivery and asset management solutions. TUG, Aethon’s Automated Robotic Delivery System (ARD), can transport both scheduled and on-demand hospital deliveries between all ancillary, support and patient care units. It navigates using it's own built in map and sensors and doesn't require a staging area or special infrastructure. Used in over 140 hospitals and reportedly makes over 50k deliveries per week. Aethon's MedEx software helps pharmacies track medication deliveries in real time using RFID.
Key facts about Aethon
- Founded Year: 1997
- Location: Pittsburgh (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $55.3M
- Employee Count: 106 as on Mar 31, 2026
- Investors: NMT Capital, Ascension Ventures and 12 Others
- Latest Funding Round: Series C, Dec 20, 2013, $*****
- Highlight: Acquired
Developer of therapies for rare and orphan diseases. It has a pipeline of small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases. These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. Its drug pipeline includes migalastat, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, and SD-101 for the treatment of the rare genetic connective tissue disorder Epidermolysis Bullosa (EB).
Key facts about Amicus Therapeutics
- Founded Year: 2002
- Location: Philadelphia (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $91M
- Employee Count: 619 as on May 31, 2026
- Investors: Avoro Capital, Frazier Life Sciences and 10 Others
- Latest Funding Round: Post IPO, Oct 02, 2023, $*****
- Highlight: Acquired
Developer of therapeutics for antibiotic-resistant infections. The company develops broad-spectrum antibiotics like Baxdela, Vabomere, Orbactiv, and Rezzayo for hospital and acute care settings. It emphasizes a patient-focused portfolio of commercial-stage antimicrobials and antifungals.
Key facts about Melinta Therapeutics
- Founded Year: 2000
- Location: Morristown (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2018
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $186M
- Employee Count: 62 as on Sep 30, 2026
- Investors: Oberland Capital, Saints Capital and 16 Others
- Latest Funding Round: Post IPO, Feb 22, 2019, $*****
- Highlight: Acquired
Endoluminal solutions for digestive diseases, restoring anatomy and improving patient outcomes. They specialize in minimally invasive therapies for gastroesophageal reflux disease (GERD), offering innovative medical devices and procedures designed to restore the natural state of the anatomy. Their flagship technology provides a lower side-effect profile compared to alternative options, improving the quality of life for patients. They are committed to training and education for healthcare providers, ensuring proper technique and optimal patient results. They focus on community outreach and adhere to regulatory labeling standards, prioritizing patient safety and ethical practices. They offer a comprehensive approach to GERD treatment, providing support and resources for both patients and providers.
Key facts about EndoGastric Solutions
Radius Ventures' Investments by Stage
Radius Ventures has made 11 investments in Series B stage with an average round size of $14.9M, 7 investments in Series A stage with an average round size of $9.97M and 3 investments in Series C stage with an average round size of $51.2M.Stage of entry | No. of Investments |
|---|---|
Series B | 11 |
Series A | 7 |
Series C | 3 |
PE | 1 |
Series D | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
Radius Ventures' Investments by Sector
Radius Ventures has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, High Tech and Vertical SaaS. Notably, it has invested in 31 Enterprise (B2B) companies, 28 Tech companies, 16 Software companies and at least 9 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 17 |
Enterprise Applications | 8 |
HealthTech | 7 |
High Tech | 4 |
Vertical SaaS | 4 |
Others | 9 |
Note: We have considered here, only first round of investments
Radius Ventures' Investments by Geography
Radius Ventures has made most investments in United States (23), followed by Israel where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 23 |
Israel | 1 |
Japan | 1 |
Note: We have considered here, only first round of investments
Radius Ventures' recent investments
Radius Ventures has not made any investment in 2026 so far.Here are the most recent investments by Radius Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 03, 2018 | United States | Series I | 2099 | [+5] | |
Feb 22, 2016 | United States | Conventional Debt | 5972 | [+2] | |
Dec 01, 2015 | United States | Series H | 3126 | ||
Nov 19, 2015 | United States | Series B | 2258 | ||
Aug 19, 2014 | United States | Series E | 8408 | [+1] |
IPOs and Publicly Listed companies in Radius Ventures' Portfolio
2 of Radius Ventures' portfolio companies have become public. Tabula Rasa Healthcare got listed on the Nordic and Baltic regions (NASDAQ OMX), in Sep 2016 at marketcap of $283M and Tactile Medical got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $166M.Here are Radius Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 29, 2016 | Aug 2013 | Series A | 7939 | |
Jul 28, 2016 | Oct 16, 2012 | Series B | 4798 |
Acquired companies in Radius Ventures' Portfolio
22 companies from Radius Ventures' portfolio have been acquired. The most recent acquisition was Amicus Therapeutics in Dec 2025 by BioMarin Pharmaceutical for $*****.Here are Radius Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 19, 2025 | May 12, 2004 | Series B | 3940 | |
Aug 07, 2025 | Jun 20, 2006 | Series C | 9660 | |
Mar 25, 2024 | - | - | 3415 | |
Feb 28, 2022 | Apr 27, 2010 | Series B | 2949 | |
Aug 18, 2018 | Dec 03, 2001 | Series B | 5378 |
Team profile of Radius Ventures
Radius Ventures has a team of 6 members including 1 Partner and 2 Venture Partners located in United States. Radius Ventures' team does not sit on the board of any company as of now.Here is a list of all team members in Radius Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | ||
Venture Partner | Camp Hill | - | ||
Venture Partner | Brooklyn | - | - |
Co-investors of Radius Ventures
Over the past 26 years, 123 investors have co-invested in Radius Ventures's portfolio companies. This includes only funds.
- Invested before Radius Ventures: Galen Partners, Trident Capital and 29 others have invested in rounds before Radius Ventures. There is 1 company where Galen Partners has invested before Radius Ventures and 1 company where Trident Capital has invested before Radius Ventures.
- Top Co-investors of Radius Ventures: 48 investors entered a company along with Radius Ventures. These include investors like Canaan (3 companies).
- Invested after Radius Ventures: A total of 44 investors have invested in Radius Ventures's portfolio after their investments. Top Investors include Robert Bosch Venture Capital (1 company), Medicis (1 company) and Mitsui (1 company).
Recent News related to Radius Ventures
•
PhysicsX Raises $300M to Transform Engineering With AIVentureburn•Jun 08, 2026•PhysicsX, July Fund, NGP Capital, Siemens and 4 others
•
EndoGastric Solutions Closes Series I Financing at a Total of $45 MillionBusiness Wire•May 28, 2019•EndoGastric Solutions, Canaan, Canepa Healthcare, Chicago Growth Partners and 4 others
•
EndoGastric Solutions Secures $30.5M In New FinancingFinSMEs•Jul 10, 2018•EndoGastric Solutions, Canaan, Canepa Healthcare, Chicago Growth Partners and 3 others
•
With $57.5B invested so far in 2018, VC funding for U.S. startups reaching ‘unprecedented levels’GeekWire•Jul 09, 2018•EndoGastric Solutions, Canaan, Canepa Healthcare, Chicago Growth Partners and 3 others
•
GreatCall picks up Healthsense as Merck exitsGlobal Corporate Venturing•Dec 22, 2016•GreatCall, HealthSense, Radius Ventures, Healthsense
•
Healthsense's $2.5M bridge round will support remote monitoring customer base expansion - MedCity NewsMedCity News•Feb 24, 2016•Healthsense, Radius Ventures, Merck, Mansa Capital and 1 other
•
EndoGastric Solutions Secures $50 Million In Financing | Business WireBusiness Wire•Dec 01, 2015•EndoGastric Solutions, Advanced Technology Ventures, Chicago Growth Partners, Canaan and 3 others
•
Startup gets $50M for "natural orifice" device to treat GERDMedCity News•Dec 01, 2015•EndoGastric Solutions, Advanced Technology Ventures, Chicago Growth Partners, Canaan and 3 others
•
Meet Healthsense, Provider of Health Monitoring SystemsHealthsense•Feb 09, 2015•Healthsense, Mansa Capital, Radius Ventures, Merck
•
Healthsense Closes $10 Million Financing with Boston-Based Mansa CapitalHealthsense•Aug 19, 2014•Healthsense, Mansa Capital, Radius Ventures, Merck
